autologous tumor-infiltrating lymphocyte therapy (Vall d'Hebron Institute of Oncology/Banc de Sang i Teixits)
N/A
Report date: 2025/02/01 20:00:06
Base Information
Drug Nameautologous tumor-infiltrating lymphocyte therapy (Vall d'Hebron Institute of Oncology/Banc de Sang i Teixits)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesVall d'Hebron Institut d'Oncologia
China Registration ClassN/A
Develop Information
Active CompaniesVall d'Hebron Institut d'OncologiaBanc De Sang I Teixits
Inactive CompaniesN/A
Active Indications
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A